GLP-1 and hair loss: what we know about shedding

Hair loss has been reported during treatment with some GLP-1-based weight-management medicines. The evidence does not establish that the medicine directly damages hair follicles or causes permanent baldness. Weight change, reduced food intake and other hair-loss conditions can overlap, making the cause harder to identify.

If you are noticing more shedding, discuss it with your prescribing clinician. Do not start, stop, reduce or otherwise change prescription medication without that discussion. A scalp assessment and a review of what has changed are more useful than assuming one explanation.

Is hair loss reported with GLP-1 medicines?

Yes. Hair loss appears in the US prescribing information for Wegovy, which contains semaglutide, and Zepbound, which contains tirzepatide. Tirzepatide acts on both GIP and GLP-1 receptors; it is often grouped with GLP-1 treatments in everyday discussion, but is a dual-receptor medicine.

The following figures come from adult weight-management trials in the FDA Wegovy information and FDA Zepbound information, checked on 3 October 2026. Doses identify the study groups; they are not dosing advice.

Both labels describe the reported hair loss as associated with weight reduction. These are reports during specific trials, not a forecast of your own risk. They also do not tell us how much was temporary shedding versus another hair-loss condition. Comparing percentages across different trials is not a head-to-head comparison of the medicines.

These injection results should not be applied automatically to other semaglutide formulations, doses or every medicine in the broader class.

What recent research adds

A 2026 systematic review and meta-analysis by Cheng and Chang combined nine interventional studies, including seven randomized trials. It found more reported hair loss with GLP-1 treatment than with placebo. This supports taking the reports seriously. It does not, by itself, separate a direct drug effect from the weight loss and dietary changes that occur during treatment.

An August 2026 matched medical-records study also found associations between semaglutide or tirzepatide use and nonscarring hair loss, including telogen effluvium. Follow-up body mass index was lower in users with hair-loss outcomes than in those without them. Because this was a retrospective study, that finding suggests a possible contribution from weight change rather than proving the reason for an individual's hair loss.

The 2026 review by Gupta and colleagues identifies recurring limitations: hair-loss type and timing are often poorly recorded, nutrition and pre-existing hair loss are not consistently accounted for, and studies differ in medicines, doses and populations. Safety-report databases can flag a concern, but reporting patterns cannot establish causation or measure how common a problem is among all users.

What about the new genetics study?

A September 2026 paper indexed in PubMed examines increased GLP-1 receptor expression and male-pattern hair loss using two-sample Mendelian randomization. This approach uses genetic information to investigate a possible biological relationship; it is not a trial assigning people a GLP-1 prescription.

The distinction matters when interpreting headlines. A genetic finding about receptor expression cannot be treated as an estimate of what taking a medicine will do to a patient's hair. It leaves a question for further investigation, rather than establishing medication-induced baldness.

Is the medication itself responsible?

It may be part of the picture, but a direct effect has not been established separately from other changes during treatment. The existing evidence does not justify saying either that the medicines definitely cause hair loss directly or that every episode is explained entirely by weight loss.

Different questions need different evidence: whether people report more shedding during treatment, whether a medicine acts directly on a follicle, and what caused one person's symptoms are not interchangeable. The trials and reviews support an association; the precise contribution of medication, weight change, nutrition and other conditions remains uncertain.

How weight change can lead to delayed shedding

Telogen effluvium is excessive shedding after a disruption to the hair cycle. More follicles than usual enter the resting and shedding phase. Marked weight loss and extreme dieting are recognized triggers, alongside illness, surgery, childbirth and major stress.

The change is often delayed: shedding can become noticeable around three months after a trigger. That means the relevant history may extend back well before the week you noticed more hair in the shower. Timing is a clue to discuss, not a way to diagnose yourself.

The American Academy of Dermatology's shedding guidance explains that excessive shedding often settles as the body readjusts. Visible fullness can take many months to recover, and an ongoing trigger can prolong shedding. Those general expectations for telogen effluvium are not a guarantee about every case during GLP-1 treatment.

Telogen effluvium and pattern hair loss are different

Pattern hair loss has an inherited component and may progress over time. The AAD's female-pattern hair-loss guide describes why a widening part or gradual thinning needs assessment rather than automatic attribution to a recent medicine.

The British Association of Dermatologists notes that telogen effluvium and pattern hair loss can appear together; shedding may bring an underlying pattern to attention. A photograph or a list of symptoms cannot reliably distinguish them. Improvement in shedding does not necessarily resolve coexisting pattern hair loss.

Reduced food intake and nutrition

Eating less does not automatically mean you have a nutrient deficiency. However, a joint advisory from four medical organizations highlights the need to assess intake and manage gastrointestinal side effects during GLP-1 treatment. The advisory has a 2026 correction to one dietary-counseling study description; that study should not be read as proof that counseling prevents hair loss.

The AAD's practical hair-loss guidance notes that too few calories or inadequate intake of nutrients such as protein and iron can contribute to hair loss. This makes nutrition worth reviewing, but does not prove deficiency is the main cause of every episode during GLP-1 treatment.

Tell your clinician if nausea, vomiting or very low appetite makes it difficult to eat. A registered dietitian can help adapt meals to your medical needs and preferences. Our vegetarian protein food guide and practical lunch ideas offer ordinary meal-planning options; they are not treatments for shedding or a replacement for an individual nutrition assessment.

There is no established universal supplement plan for this problem. NIH's biotin guidance notes limited evidence for hair benefits in people without a relevant deficiency and warns that supplements can interfere with laboratory tests. Tell your care team about supplements you already take rather than adding high-dose biotin on your own.

What to do if you notice a change

1. Contact your prescribing clinician. Explain the hair change and any difficulty eating. Discuss the medicine's benefits, side effects and your concerns together; do not adjust treatment yourself.
2. Bring a short timeline. Note when treatment and shedding began, changes in weight or food intake, recent illness or surgery, and other medicines or supplements. Occasional photographs in similar lighting may help you describe the change without counting every hair.
3. Ask whether a scalp assessment is needed. A clinician can consider telogen effluvium, pattern hair loss and other causes. Tests for issues such as iron deficiency or thyroid disease depend on the history and examination; everyone does not need the same test panel.
4. Use gentle hair care. Avoid forceful brushing, tight styles and excessive heat. These steps reduce avoidable damage; they do not establish or treat the underlying cause.

MedlinePlus explains the assessment process, including questions about diet, recent illness, family history and the pattern of hair loss. The AAD's care advice supports gentle handling and checking a possible deficiency before turning to marketed hair-growth supplements.

When to seek medical evaluation

Arrange an assessment for new hair loss that concerns you; you do not have to wait for it to become severe. MedlinePlus advises contacting a healthcare professional for unusual or rapid hair loss, pain or itching, a red or scaly scalp, or hair loss with other symptoms such as fatigue.

Seek prompt assessment for distinct bald patches, scalp inflammation or loss of eyebrow hair rather than assuming ordinary weight-related shedding. Also follow up if shedding continues for several months or the pattern keeps changing. Telogen effluvium lasting more than six months is considered chronic, but that is a classification, not an instruction to delay care.

Persistent vomiting or diarrhea during treatment deserves prompt contact with your prescribing team because of dehydration risk, as the FDA medicine information explains. A hair-loss article should not distract from a treatment side effect that is making you unwell.

Frequently asked questions

Does GLP-1 treatment cause permanent baldness?

Current evidence does not establish that GLP-1 medicines cause permanent baldness. Telogen effluvium often improves, while pattern hair loss and other conditions have different courses. Getting the type of hair loss assessed is more useful than assuming all shedding is temporary.

Can shedding happen without a GLP-1 medicine?

Yes. Marked weight loss, extreme dieting, illness and other physical or emotional stresses can trigger telogen effluvium independently of these medicines. Hair loss also has causes unrelated to weight change.

Should I stop treatment until the shedding settles?

Do not stop or change a prescription on your own. Contact the prescribing clinician so the hair change, nutritional intake and treatment benefits can be assessed together.

Will extra protein or biotin fix it?

Correcting inadequate intake or a diagnosed deficiency may be part of care, but more protein or a hair supplement is not a proven universal remedy for shedding during GLP-1 treatment. Food needs and any supplementation should be matched to your situation.

This article provides general adult health information. It cannot diagnose your hair loss or determine whether a medicine is right for you. Read our health disclaimer for the boundaries of this information.